Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Shared decision making honors patient autonomy, particularly for preference-sensitive care decisions and even when patients have impaired decision-making capacity.
AMA J Ethics. 2020;22(5):E358-364. doi:
10.1001/amajethics.2020.358.
Legacy patients are so-called because their opioid use behaviors express past, aggressive opioid prescribing by a clinician. Managing their pain and dependence justly is ethically complex.
AMA J Ethics. 2020;22(8):E651-657. doi:
10.1001/amajethics.2020.651.
Annika Brakebill, A. Mark Fendrick, MD, and Jeffrey T. Kullgren, MD, MS, MPH
These key steps are ones health sector stakeholders should take to help patients and clinicians use pricing information to inform health decision making.
AMA J Ethics. 2022;24(11):E1034-1039. doi:
10.1001/amajethics.2022.1034.